entertainment -WSS

entertainment

author：fashion 2025-09-05 09:18:21 - browse：34715

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： RSV injection headlines need to be accurate for good uptake

leisure time

WSS

WHO recommends second malaria vaccine

Lawsuit highlights wrinkle for disputes over surprise medical bills

With Roe v Wade overturned, abortion providers work to adapt

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Flu, Covid vaccination rates decline, new survey data show

Chris Christie meets with Zelenskyy during Ukraine trip

focus

entertainment

The need-to-know this morning

Is it time to worry about Moderna?

focus

Supreme Court strikes down use of affirmative action

Study links childhood stress with decline in older age

Apple is now the first public company to be valued at $3 trillion

Group behind ProMed defends move to subscription

In age of alternative facts, a scholarly course on calling out crap

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Trump demands the U.S. pay no more for drugs than other countries … again

Study points to new risk in gene therapy death of Terry Horgan

What does generative AI mean for health care? We asked experts

The a glaring gap in research on serious mental illness and primary care

hotspot

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Experts study whether long Covid risk adds up with each reinfection

The cancer stories no one wants to hear

How to ethically and practically extend health care to all

The Karikó problem: Lessons for funding basic research

New oral drug delivery patch is modeled after octopus tentacles

entertainment

entertainment

leisure time

hotspot